SGMO
Sangamo Therapeutics·NASDAQ
--
--(--)
--
--(--)
SGMO fundamentals
Sangamo Therapeutics (SGMO) expects to report earnings on Mar 30, 2026, with estimated revenue of 40.23M (YoY +432.71%), and EPS at 0.009 (YoY +108.18%).
Revenue estimate / YoY
40.23M
+432.71%
EPS estimate / YoY
0.009
+108.18%
Report date
Mar 30, 2026
SGMO Earnings Call Summary for Q4,2025
- Fabry BLA Progress: Rolling submission underway; clinical and preclinical modules submitted. CMC completion expected by summer 2026, contingent on funding. ST-920 data show stabilized kidney and cardiac function in patients.
- Neurology Expansion: ST-503 Phase I/II study active at 6 sites; received FDA Fast Track for SFN. ST-506 advancing with toxicology study complete.
- Partnership Focus: Prioritizing Fabry commercialization partner; discussions with multiple new partners despite regulatory delays. $130M+ raised since 2025 through licensing and equity.
- Capsid Innovation: Third STAC-BBB capsid agreement with Eli Lilly for CNS targets. AAV9 used for ST-503 due to historical intrathecal efficacy.
Earnings
EPS
Revenue
Revenue & Expenses
SGMO has released its 2025 Q4 earnings report, with revenue of 14.23M, reflecting a YoY change of 88.43%, and net profit of -37.42M, showing a YoY change of -59.94%. The Sankey diagram below clearly presents SGMO's revenue sources and cost distribution.
Key Indicators
Sangamo Therapeutics (SGMO) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
Sangamo Therapeutics (SGMO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
Sangamo Therapeutics (SGMO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
Sangamo Therapeutics (SGMO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does Sangamo Therapeutics (SGMO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track Sangamo Therapeutics (SGMO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Sangamo Therapeutics's earnings call?What is the market's earnings forecast for Sangamo Therapeutics next quarter?Did Sangamo Therapeutics beat or miss consensus estimates last quarter?What is Sangamo Therapeutics's gross profit margin?What guidance did Sangamo Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Sangamo Therapeutics year over year?What were the key takeaways from Sangamo Therapeutics’s earnings call?What does Sangamo Therapeutics do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
